This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Janet B. Henrich, MD

JAMA. 1992;268(14):1900-1902.

Abstract
Objective.
—To provide an overview of the postmenopausal estrogen/breast cancer controversy emphasizing the sources of disagreement in the literature and their clinical and research implications.

Data Source and Selection.
—A MEDLINE search of the English-language literature and a review of bibliographies of meta-analyses describing the association between postmenopausal estrogen use and breast cancer risk.

Data Extraction.
—Twenty-four original articles and three meta-analyses were reviewed. In addition, five studies that attempted to minimize detection bias were reviewed to assess the potential role of this bias on risk estimates.

Data Synthesis.
—Among the original articles, risk estimates ranged from a protective to an adverse effect in women who ever used estrogens; no consistent quantitative effects of estrogens on breast cancer risk were found. In the meta-analyses, summary risk estimates were not significantly elevated in women who ever used estrogen. Findings from European-based studies may account for the increased risk associated with increasing duration of use reported in one meta-analysis. In studies that controlled for detection bias, risk estimates were 1 or less in the ever-used category; there was no consistent effect across other categories of use.

Conclusion.
—These findings do not support an overall increased risk of breast cancer in women who ever used postmenopausal estrogens or a conclusive or consistent effect across other measures of use. Cross-national differences in estrogen use and inequalities in breast cancer detection between estrogen users and nonusers may account for the increased risk estimates reported in some studies. Newer estrogen and progestin-opposed regimens need to be evaluated further.

(JAMA. 1992;268:1900-1902)

Author Affiliations
From the Department of Medicine, Yale University School of Medicine, New Haven, Conn.

Footnotes
Reprint requests to Primary Care Center, Yale-New Haven Hospital, 20 York St, New Haven, CT 06504 (Dr Henrich).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Organochlorine Residues and Risk of Breast Cancer
Houghton and Ritter
International Journal of Toxicology 1995;14:71-89.
ABSTRACT  

Estrogen Replacement Therapy in Breast Cancer Survivors: A Time for Change
Cobleigh et al.
JAMA 1994;272:540-545.
ABSTRACT  

Coronary Artery Disease in Women: Risk Factors, Evaluation, Treatment, and Prevention
Kuhn and Rackley
Arch Intern Med 1993;153:2626-2636.
ABSTRACT  

The Postmenopausal Estrogen/Breast Cancer Controversy
Grady and Rubin
JAMA 1993;269:990-990.
ABSTRACT  

The Postmenopausal Estrogen/Breast Cancer Controversy
Vassilopoulou-Sellin
JAMA 1993;269:991-991.
ABSTRACT  

ESTROGENS AND BREAST CANCER: EVIDENCE IS WEAK
JWatch General 1992;1992:4-4.
FULL TEXT  

Women's Health Research: Prescribing Change and Addressing the Issues
Pinn
JAMA 1992;268:1921-1922.
ABSTRACT